GO:1905883 regulation of triglyceride transport: Lipid Homeostasis Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1905883 (regulation of triglyceride transport) is a biological process term defined as any process that modulates the frequency, rate or extent of triglyceride transport [QuickGO].
• Triglyceride transport is essential for delivering fatty acids from the liver and intestine to peripheral tissues for energy and storage [1,2].
• Key proteins include apolipoproteins (APOB, APOC3), microsomal triglyceride transfer protein (MTTP), and phospholipase PLA2G12B [2,4].
• Dysregulation of triglyceride transport contributes to metabolic diseases such as atherosclerosis, fatty liver disease, and insulin resistance [1,6].
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable precise dissection of regulatory mechanisms [4,7].
• Understanding this process informs therapeutic strategies targeting triglyceride-rich lipoproteins and associated disorders [2,6].
Description
Triglycerides (triacylglycerols) are the primary form of stored energy in animals and are transported through the bloodstream as part of triglyceride-rich lipoproteins (TRLs), including chylomicrons and very-low-density lipoproteins (VLDL) [1,2]. The regulation of triglyceride transport (GO:1905883) encompasses all processes that modulate the movement of triglycerides between tissues, a critical aspect of lipid homeostasis [1,2]. This regulation ensures that fatty acids are delivered to peripheral tissues for oxidation or storage while preventing excessive accumulation in the liver and vasculature [1,2]. Dysregulation of triglyceride transport is a hallmark of metabolic disorders such as hypertriglyceridemia, non-alcoholic fatty liver disease (NAFLD), and atherosclerosis [1,6]. Therefore, understanding the molecular players and regulatory mechanisms is essential for developing targeted therapies [2,6]. Recent studies have identified novel regulators, including PLA2G12B, which drives the expansion of TRLs, and acylation-stimulating protein (ASP), which coordinates triglyceride synthesis and glucose transport [4,5]. This article provides a comprehensive overview of GO:1905883, integrating authoritative QuickGO data with verified PubMed literature. We cover the definition, biological significance, key genes, regulatory mechanisms, disease associations, and state-of-the-art research methods, including CRISPR-based models. The content is designed to support researchers, clinicians, and students in understanding and investigating triglyceride transport regulation.
regulation of triglyceride transport At A Glance
| GO ID | GO:1905883 |
|---|---|
| GO term | regulation of triglyceride transport |
| Ontology | biological_process |
| Synonym | regulation of triacylglycerol transport |
| Major function | Modulates the frequency, rate or extent of triglyceride transport |
| Related processes | Lipoprotein assembly, lipid absorption, fatty acid uptake |
| Key regulators | APOB, APOC3, MTTP, PLA2G12B, ASP |
| Disease relevance | Hypertriglyceridemia, NAFLD, atherosclerosis, insulin resistance |
What Is GO:1905883?
GO:1905883, regulation of triglyceride transport, is defined as any process that modulates the frequency, rate or extent of triglyceride transport [QuickGO]. In other words, it includes all molecular events that control how triglycerides are moved within and between cells and tissues, such as the assembly and secretion of triglyceride-rich lipoproteins, their lipolysis in the bloodstream, and the uptake of fatty acids by target tissues [1,2]. This regulation is vital for energy balance and lipid homeostasis.
Why Is regulation of triglyceride transport Important in Cell Biology?
Regulation of triglyceride transport is fundamental to systemic energy homeostasis and cardiovascular health. It ensures efficient delivery of fatty acids from the intestine and liver to peripheral tissues, while preventing lipotoxicity in the liver and arteries [1,2]. Dysregulation leads to hypertriglyceridemia, a risk factor for atherosclerosis and pancreatitis, and is closely linked to insulin resistance and type 2 diabetes [1,6]. Moreover, triglyceride transport influences hepatic steatosis and NAFLD progression. Thus, deciphering its regulatory mechanisms offers therapeutic opportunities for metabolic diseases [2,6].
• Maintains energy balance by distributing fatty acids to tissues for oxidation or storage.
• Prevents hepatic steatosis and lipotoxicity by regulating VLDL secretion [1,2].
• Influences plasma triglyceride levels, a key risk factor for cardiovascular disease.
• Modulates intestinal fat absorption and chylomicron formation.
• Impacts insulin sensitivity and glucose homeostasis through ASP and other regulators.
• Plays a role in Drosophila lipid metabolism, offering a genetic model.
• Targeted by fibrates and other lipid-lowering drugs.
• Involved in the pathogenesis of NAFLD and atherosclerosis [1,2].
• Provides a paradigm for studying membrane transport and lipoprotein biology [2,4].
• Offers opportunities for CRISPR-based functional genomics [4,7].
What Happens During regulation of triglyceride transport?
Triglyceride Synthesis and Lipoprotein Assembly
In simple terms: The body builds triglycerides and packages them into lipoproteins for transport.
Triglycerides are synthesized in the liver and intestine via the esterification of fatty acids to glycerol. In the liver, this process is regulated by enzymes such as diacylglycerol acyltransferase (DGAT) and is coupled to the assembly of very-low-density lipoproteins (VLDL). In the intestine, triglycerides are packaged into chylomicrons. The assembly of these triglyceride-rich lipoproteins requires apolipoprotein B (APOB) and microsomal triglyceride transfer protein (MTTP). Recent studies have identified PLA2G12B as a key regulator of TRL expansion.
Secretion of Triglyceride-Rich Lipoproteins
In simple terms: The packaged lipoproteins are released into the bloodstream.
Once assembled, TRLs are secreted from hepatocytes and enterocytes into the circulation. This secretion is regulated by factors such as APOC3, which inhibits lipoprotein lipase (LPL) and hepatic lipase, thereby modulating plasma triglyceride levels. The regulation of secretion is critical for maintaining lipid homeostasis, and its dysregulation leads to hypertriglyceridemia [1,6].
Lipolysis and Fatty Acid Uptake
In simple terms: In the blood, triglycerides are broken down and fatty acids are taken up by tissues.
In the bloodstream, TRLs undergo lipolysis by LPL, releasing free fatty acids that are taken up by peripheral tissues such as muscle and adipose tissue. This process is regulated by apolipoproteins (e.g., APOC2 as an LPL activator, APOC3 as an inhibitor) and by hormones like insulin [2,6]. Acylation-stimulating protein (ASP) coordinates triglyceride synthesis and glucose transport in adipocytes, linking lipid and glucose metabolism.
Intestinal Triglyceride Absorption
In simple terms: Dietary fats are absorbed in the gut and transported as chylomicrons.
Dietary triglycerides are hydrolyzed by pancreatic lipase and absorbed by enterocytes, where they are re-esterified and packaged into chylomicrons. This process is regulated by factors such as the cholesterol transporter NPC1L1 and the triglyceride absorption machinery. Recent developments highlight the role of intestinal cholesterol and triglyceride transporters in this regulation.
Regulation by Hormones and Nutritional Status
In simple terms: Hormones and diet control how fast triglycerides are transported.
Insulin promotes triglyceride storage and inhibits lipolysis, while glucagon and fasting stimulate fatty acid release. Fibrates, which activate PPARα, lower plasma triglycerides by increasing fatty acid oxidation and reducing VLDL secretion. These regulatory mechanisms ensure that triglyceride transport adapts to the body's energy needs [1,6].
Key Genes Involved in GO:1905883 regulation of triglyceride transport
The following genes and proteins are central to the regulation of triglyceride transport, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| APOB | Structural component of VLDL and chylomicrons; required for TRL assembly | Mutations cause familial hypobetalipoproteinemia; target for lipid-lowering therapies |
| APOC3 | Inhibits lipoprotein lipase and hepatic lipase; increases plasma triglycerides | Loss-of-function mutations associated with lower triglycerides and cardiovascular risk |
| MTTP | Microsomal triglyceride transfer protein; essential for APOB lipidation | Mutations cause abetalipoproteinemia; target for treating hypertriglyceridemia |
| PLA2G12B | Phospholipase that drives expansion of triglyceride-rich lipoproteins | Novel regulator identified in zebrafish and human cells; potential therapeutic target |
| ASP (C3a desArg) | Acylation-stimulating protein; coordinates triglyceride synthesis and glucose transport | Links lipid and glucose metabolism; implicated in obesity and insulin resistance |
| LPL | Lipoprotein lipase; hydrolyzes triglycerides in TRLs | Deficiency causes hypertriglyceridemia; regulated by apolipoproteins |
| APOC2 | Activator of lipoprotein lipase | Deficiency causes hyperlipoproteinemia type Ib |
| DGAT1/2 | Diacylglycerol acyltransferase; catalyzes final step of triglyceride synthesis | Involved in hepatic steatosis and lipid storage |
| PPARα | Nuclear receptor; regulates fatty acid oxidation and triglyceride metabolism | Target of fibrates; lowers plasma triglycerides |
| NPC1L1 | Intestinal cholesterol and triglyceride absorption | Target of ezetimibe; regulates dietary lipid uptake |
| FABP | Fatty acid binding proteins; facilitate intracellular fatty acid transport | Modulate lipid trafficking and metabolism |
| SREBP-1c | Transcription factor; promotes lipogenesis and triglyceride synthesis | Regulated by insulin; contributes to hepatic steatosis |
| FoxO1 | Transcription factor; regulates VLDL secretion and lipid metabolism | Implicated in insulin resistance and NAFLD |
| PCSK9 | Regulates LDL receptor; indirectly affects triglyceride metabolism | Target of evolocumab; impacts TRL clearance |
| ANGPTL3 | Inhibits lipoprotein lipase and endothelial lipase | Loss-of-function mutations lower triglycerides; therapeutic target |
| APOA5 | Enhances lipoprotein lipase activity | Variants associated with hypertriglyceridemia |
| GPIHBP1 | Endothelial protein that anchors LPL | Deficiency causes hypertriglyceridemia |
| CREBH | Transcription factor; regulates triglyceride metabolism in liver | Implicated in NAFLD and metabolic syndrome |
How Is regulation of triglyceride transport Regulated?
The regulation of triglyceride transport is tightly controlled by hormonal and nutritional signals. Insulin promotes triglyceride synthesis and storage while inhibiting lipolysis, whereas glucagon and fasting stimulate fatty acid release. The transcription factor PPARα, activated by fibrates, enhances fatty acid oxidation and reduces VLDL secretion, thereby lowering plasma triglycerides. Additionally, acylation-stimulating protein (ASP) coordinates triglyceride synthesis and glucose transport, linking lipid and glucose homeostasis. In the intestine, cholesterol and triglyceride absorption is regulated by NPC1L1 and other transporters. These regulatory pathways ensure that triglyceride transport adapts to the body's energy demands and are often dysregulated in metabolic diseases [1,6].
regulation of triglyceride transport and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| APOC3 | Hypertriglyceridemia, cardiovascular disease | Knockout mouse, human hepatocytes |
| MTTP | Abetalipoproteinemia, hepatic steatosis | Liver-specific knockout mouse |
| PLA2G12B | Hypertriglyceridemia, TRL expansion | Zebrafish knockout, CRISPR in HepG2 cells |
| ASP (C3) | Obesity, insulin resistance | Adipocyte-specific knockout mouse |
| LPL | Hyperlipoproteinemia type I | Knockout mouse, patient-derived iPSCs |
Hypertriglyceridemia and Cardiovascular Disease
Elevated plasma triglycerides are an independent risk factor for atherosclerosis and cardiovascular disease. Dysregulation of triglyceride transport, often due to mutations in APOC3, APOA5, LPL, or GPIHBP1, leads to hypertriglyceridemia. Fibrates, which activate PPARα, are used to lower triglycerides and reduce cardiovascular risk.
Non-Alcoholic Fatty Liver Disease (NAFLD)
Impaired hepatic triglyceride secretion contributes to hepatic steatosis and NAFLD progression. Dysregulation of VLDL assembly and secretion, involving MTTP and APOB, leads to fat accumulation in the liver [1,2]. Insulin resistance and altered transcription factor activity (e.g., SREBP-1c, FoxO1) exacerbate this condition.
Obesity and Insulin Resistance
Acylation-stimulating protein (ASP) coordinates triglyceride synthesis and glucose transport, and its dysregulation is implicated in obesity and insulin resistance. ASP enhances triglyceride clearance and glucose uptake, linking lipid and glucose metabolism. Targeting ASP pathways may offer therapeutic benefits for metabolic syndrome.
Intestinal Lipid Absorption Disorders
Defects in intestinal triglyceride absorption can cause malabsorption and steatorrhea. NPC1L1 and other transporters regulate dietary lipid uptake, and their dysfunction is linked to metabolic disorders. Understanding these mechanisms is crucial for developing treatments for lipid malabsorption.
From regulation of triglyceride transport-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate triglyceride secretion? | CRISPR knockout in HepG2 or primary hepatocytes |
| Does a point mutation in APOC3 affect LPL inhibition? | CRISPR point mutation knock-in in cell lines |
| Does overexpression of PLA2G12B increase TRL expansion? | CRISPR overexpression (CRISPRa) in zebrafish or cells |
| Does tagging endogenous MTTP affect its localization? | Knock-in of fluorescent tag (e.g., GFP) using CRISPR |
| Does intestinal-specific knockout of NPC1L1 alter fat absorption? | Tissue-specific CRISPR knockout in mouse |
| Does a regulatory variant affect APOA5 expression? | CRISPR knock-in of variant in hepatocytes |
How to Study the regulation of triglyceride transport Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screening | Loss-of-function phenotypes | Identify novel regulators of triglyceride transport |
| Lipidomics (LC-MS) | Triglyceride species and abundance | Quantify lipid changes in cells or plasma |
| Live-cell imaging | Real-time lipoprotein secretion | Visualize VLDL trafficking in hepatocytes |
| RNA-seq | Transcriptional changes | Profile gene expression after genetic perturbation |
| Proteomics | Protein abundance and interactions | Identify protein complexes in TRL assembly |
| Western blot | Protein expression levels | Validate knockout or overexpression |
| Triglyceride assay kit | Triglyceride concentration | Measure cellular or plasma triglycerides |
| Lipoprotein profiling | Size and composition of lipoproteins | Analyze TRL fractions from plasma |
CRISPR Screening for Regulators of Triglyceride Transport
Genome-wide CRISPR knockout or activation screens can identify novel regulators of triglyceride transport. For example, a screen in hepatocytes could use a fluorescent triglyceride reporter to sort cells with altered lipid storage. This approach has been used to discover PLA2G12B as a key regulator of TRL expansion.
Lipidomics and Mass Spectrometry
Mass spectrometry-based lipidomics quantifies triglyceride species and other lipids in cells and plasma. This method can assess the impact of genetic perturbations on triglyceride synthesis, secretion, and uptake [1,2].
Live-Cell Imaging of Lipoprotein Secretion
Fluorescently tagged apolipoproteins (e.g., APOB-GFP) enable real-time visualization of VLDL assembly and secretion in hepatocytes. This technique reveals dynamics of triglyceride transport under different conditions.
RNA-Seq and Proteomics
Transcriptomic and proteomic profiling of cells or tissues with genetic modifications can uncover pathways and networks regulated by candidate genes. For instance, RNA-seq of APOC3 knockout hepatocytes reveals changes in lipid metabolism genes.
How CRISPR Can Be Used to Study GO:1905883 regulation of triglyceride transport
Knockout
CRISPR knockout of candidate genes (e.g., APOC3, MTTP, PLA2G12B) in cell lines or animal models allows researchers to assess their necessity in triglyceride transport. For example, knockout of PLA2G12B in zebrafish reduces TRL expansion. Knockout models are essential for validating gene function and identifying compensatory pathways.
Point Mutation
CRISPR point mutation knock-in introduces specific disease-associated variants (e.g., APOC3 R19X) to study their impact on protein function and triglyceride transport. This approach provides precise genotype-phenotype correlations and can model human mutations in isogenic cell lines.
Knock-in
Knock-in of reporter tags (e.g., GFP, luciferase) or regulatory elements enables tracking of endogenous proteins and their dynamics. For instance, tagging MTTP with GFP allows visualization of its localization and trafficking in hepatocytes. Knock-in models are valuable for studying protein interactions and real-time regulation.
Overexpression
CRISPR activation (CRISPRa) or traditional overexpression vectors can increase gene expression to study gain-of-function effects. Overexpression of PLA2G12B in zebrafish enhances TRL expansion, confirming its role as a positive regulator. Overexpression models help identify sufficiency and potential therapeutic targets.
How EDITGENE Supports regulation of triglyceride transport Research
Researchers studying regulation of triglyceride transport-related genes often need to determine whether a candidate gene is causally involved in lipid homeostasis, and to dissect the precise molecular mechanisms. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research, from gene knockout to precise point mutations and overexpression.
Contact EDITGENE today to design your custom CRISPR model for regulation of triglyceride transport research.
Frequently Asked Questions About regulation of triglyceride transport
What is GO:1905883?
GO:1905883 is the Gene Ontology term for 'regulation of triglyceride transport', defined as any process that modulates the frequency, rate or extent of triglyceride transport [QuickGO].
What genes are involved in regulation of triglyceride transport?
Key genes include APOB, APOC3, MTTP, PLA2G12B, LPL, APOA5, and ASP, among others [2,4,5].
How is triglyceride transport regulated?
It is regulated by hormones (insulin, glucagon), apolipoproteins, lipases, and transcription factors such as PPARα [1,6].
What diseases are associated with dysregulation of triglyceride transport?
Hypertriglyceridemia, atherosclerosis, NAFLD, obesity, and insulin resistance [1,2,5,6].
What is the role of APOC3 in triglyceride transport?
APOC3 inhibits lipoprotein lipase and hepatic lipase, thereby increasing plasma triglycerides.
How can CRISPR be used to study triglyceride transport?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise manipulation of genes to study their function in triglyceride transport [4,7].
What is PLA2G12B and how does it relate to triglyceride transport?
PLA2G12B is a phospholipase that drives the expansion of triglyceride-rich lipoproteins, as identified in recent studies.
What are triglyceride-rich lipoproteins?
They are lipoproteins such as chylomicrons and VLDL that carry triglycerides in the bloodstream.
How does the intestine regulate triglyceride absorption?
Intestinal triglyceride absorption involves hydrolysis, uptake by enterocytes, and packaging into chylomicrons, regulated by transporters like NPC1L1.
What methods are used to study regulation of triglyceride transport?
Methods include CRISPR screening, lipidomics, live-cell imaging, RNA-seq, and proteomics [1,2,4].
Conclusion
Regulation of triglyceride transport (GO:1905883) is a vital biological process that maintains lipid homeostasis and energy balance. Its dysregulation underlies prevalent metabolic diseases, making it a prime target for therapeutic intervention. Advances in CRISPR technology and omics approaches continue to unravel the complex regulatory networks involved. EDITGENE's comprehensive services empower researchers to dissect these mechanisms with precision and efficiency.
References
- 1. Alves-Bezerra M et al.. 2017. Triglyceride Metabolism in the Liver.. Compr Physiol 8(1):1-8 PMID: 29357123
- 2. Zhang L et al.. 2025. The biogenesis and transport of triglyceride-rich lipoproteins.. Trends Endocrinol Metab 36(3):262-277 PMID: 39164120
- 4. Thierer JH et al.. 2024. Pla2g12b drives expansion of triglyceride-rich lipoproteins.. Nat Commun 15(1):2095 PMID: 38453914
- 5. Germinario R et al.. 1993. Coordinate regulation of triacylglycerol synthesis and glucose transport by acylation-stimulating protein.. Metabolism 42(5):574-80 PMID: 8492712
- 6. Fruchart JC et al.. 2006. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.. Drugs Today (Barc) 42(1):39-64 PMID: 16511610
- 7. Paalvast Y et al.. 2017. Developments in intestinal cholesterol transport and triglyceride absorption.. Curr Opin Lipidol 28(3):248-254 PMID: 28338522
- 8. Heier C et al.. 2018. Triacylglycerol Metabolism in Drosophila melanogaster.. Genetics 210(4):1163-1184 PMID: 30523167
